Fosun Pharmaceutical: the product of the subsidiary company is unqualified in the spot check; it is the cause of accidental equipment

On October 27, Fosun Pharmaceutical released the enterprise announcement that one batch of "piperacillin sodium and tazobactam sodium for injection (specification: 2.25g)" produced by Suzhou Erye Pharmaceutical Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (hereinafter referred to as "Suzhou Erye") did not meet the requirements after the spot check by Liaoning Pharmaceutical Inspection and testing institute, and the items that did not meet the requirements were content test Fixed According to the investigation of Suzhou Erye and Suzhou municipal market supervision and Administration Bureau, the unqualified products of this batch are accidental equipment reasons and no other batches are involved A total of 165200 pieces of this batch of products have been sold, with sales revenue of 1.76 million yuan At present, 52400 pieces of this batch of products retained in the market have been recalled Piperacillin sodium tazobactam sodium for injection is a compound preparation of penicillin, which is prepared by mixing piperacillin sodium and tazobactam sodium in the proportion of 8:1 and then repacking Suzhou Erye carried out a detailed investigation on the whole production process of this batch of products from the aspects of "human, machine, material, method and environment" It was confirmed that the unqualified product of this batch was due to the occasional failure of the bottom valve of the mixing equipment, resulting in the low content of "tazobactam sodium" in a small number of products in this batch, which did not affect other batches At the same time, Suzhou municipal market supervision and Administration Bureau has carried out on-site special inspection on Suzhou Erye, and confirmed again that the batch of unqualified products is accidental equipment reason and does not involve other batches through root cause investigation and drug regulatory code traceability production time Suzhou Erye is mainly engaged in the production and sales of antibiotics As of the announcement date, the registered capital of Suzhou Erye is RMB 118.42 million; its holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd holds 65% of its equity, which is its controlling shareholder In 2018, Suzhou Erye achieved operating revenue of RMB 1573.01 million and net profit attributable to the parent company of RMB 68.18 million, accounting for 6.31% of the group's operating revenue (i.e the company and its holding subsidiaries / units, the same below) and 2.52% of the shareholders' net profit attributable to the listed company in the same period; in the first half of 2019, Suzhou Erye achieved operating revenue of RMB 101, 4.02 million yuan, the net profit attributable to the parent company is 35.56 million yuan, accounting for 7.15% of the group's operating revenue and 2.35% of the net profit attributable to the shareholders of the listed company in the same period The announcement shows that the sales revenue of piperacillin sodium and tazobactam sodium for injection (specification: 2.25g) in 2018 and the first half of 2019 is about 70 million yuan and 62 million yuan respectively, accounting for 0.3% and 0.4% of the group's business revenue in the same period 3 The sales revenue of the variety "piperacillin sodium for injection tazobactam sodium (specification: 2.25g)" involved in the batch of products in question accounts for a small proportion of the group's overall operating revenue, which has no substantial impact on the normal production and operation of Fosun Pharmaceutical.